MB-dNPM1-TCR.1 in Relapsed/Refractory AML

This study is testing an experimental treatment called MB-dNPM1-TCR.1 — a type of cell therapy where specially engineered immune cells are infused to find and attack leukemia cells — in patients with relapsed or treatment-resistant acute myeloid leukemia (AML) who have limited other options. **You may be eligible if...** - You are 18 or older - You have AML that has come back or did not respond to at least two standard treatments - Your cancer carries a specific genetic change called NPM1 mutation - You have a specific immune marker called HLA-A*02:01 - You have a life expectancy of at least 3 months - Your blood counts and T cell levels meet specific thresholds **You may NOT be eligible if...** - You are pregnant - You have active, uncontrolled infection - You have another active cancer - Your organ function is severely impaired Talk to your doctor to see if this trial is right for you.